Key result
BIG reduces MI size and cardiac dysfunction in mice after ischemia-reperfusion via PI3K/AKT activation.
Why the study?
Therapeutic strategies for inhibiting extracellular matrix deposition and excessive fibrosis, which contribute to worsening cardiac function after myocardial ischaemia-reperfusion injury, have not been elucidated.
Does 4,8-dicarboxyl-8,9-iridoid-1-glycoside (BIG) improve cardiac dysfunction and reduce myocardial fibrosis after myocardial ischaemia-reperfusion injury in mice?
Does 4,8-dicarboxyl-8,9-iridoid-1-glycoside (BIG) improve cardiac dysfunction and reduce myocardial fibrosis after myocardial ischaemia-reperfusion injury in mice?
Answers are grounded in this paper and cite their sources.
BIG demonstrates therapeutic potential in reducing collagen deposition and alleviating cardiac dysfunction following myocardial ischaemia-reperfusion injury by activating the PI3K/AKT pathway.
Background Extracellular matrix (ECM) deposition and excessive fibrosis are important factors in the deterioration of cardiac function after myocardial ischaemia‒reperfusion injury (I/RI). However, therapeutic strategies for inhibiting ECM deposition and excessive fibrosis have still not been elucidated. Methods and results Single-nucleus RNA sequencing (snRNA-seq) revealed that the overexpression of type VI collagen-α 3 (Col6a3) in fibroblasts in the myocardial infarction area strongly promotes the process of myocardial fibrosis. Consistent results were not observed in the infarcted myocardial tissues of mice treated with 4,8-dicarboxyl-8,9-iridoid-1-glycoside (BIG). Echocardiography confirmed that BIG alleviated cardiac dysfunction in mice after myocardial I/RI, TTC and Evans blue double staining revealed that BIG reduced the myocardial infarction size and area at risk. BIG inhibited inflammatory responses, apoptosis, and matrix metalloproteinase (MMP) secretion both in vivo and in vitro. Immunofluorescence staining revealed that BIG downregulated the expressions of TGF‒β and Col6a3 in cardiac fibroblasts but not in cardiomyocytes. The PI3K-specific inhibitor LY294002 and AKT inhibitor were utilitzed to confirm that BIG suppressed myocardial fibrosis and alleviated cardiac dysfunction by activating the PI3K/AKT pathway. Conclusions The results provide valuable information for the treatment of myocardial fibrosis induced by myocardial I/RI and highlight the therapeutic potential of BIG in reducing collagen deposition.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied Myocardial ischaemia-reperfusion injury. 4,8-dicarboxyl-8,9-iridoid-1-glycoside (BIG) was evaluated on Cardiac dysfunction and myocardial fibrosis. 4,8-dicarboxyl-8,9-iridoid-1-glycoside (BIG) alleviated cardiac dysfunction and reduced myocardial infarction size in mice after ischaemia-reperfusion injury by activating the PI3K/AKT pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: